News

The final studies involved 150 animals that received single, repeated intra-muscular injections of PLX-PAD or a control substance then followed for up to three months post-injection. No adverse

The 420 patients enrolled in Cook’s randomized trial of its Zilver PTX drug-eluting peripheral stent include peripheral arterial disease patients treated in Germany, the US and Japan. The

According to the company, the product will be available soon in the UK and Germany, with several other European markets to follow by the end of the year

As vice president of business development, Dr Clausen, who has been a consultant to Cytomedix since May 2008, will be responsible for the coordination of the investigational new

Under the agreement GSK has exclusive options to license drug candidates from Cellzome’s kinase programs directed against four identified targets, and three additional targets to be jointly identified

The memorandum of understanding (MoU) between the Texas A&M System and Xoma covers programs for advancing healthcare research and technologies through the development of new methods, standards and

Mr Sheckler began his career with the Ross Division of Abbott Laboratories, selling nutritional and pharmaceutical products. During his time there, he served in a variety of sales

Designed to comply with the EMEA (European Medicines Agency) and FDA standards, this unit is expected to produce desensitization treatments for all markets, primarily in Europe and North

Ben Liu, founder and chief scientific officer of Plexigen, said: “We are very excited to have Bill Haas join Plexigen at this critical premarket point. Bill spent 18